April 10, 2022 12:00 PM EDTUpdated April 11, 06:32 AM

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

Max Gelman

Senior Editor

NEW ORLEANS — Amgen attempted to further pull away from Mirati Therapeutics in the KRAS space, touting a new batch of long-term non-small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

Max Gelman

Senior Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

Max Gelman

Senior Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

AACR22: Amgen reveals new long-term data for Lumakras, looking to keep pressing market advantage over Mirati

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?